News

Sapacitabine is in Phase 3 development for the treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes and lung cancer. According to

The patent is a part of patent portfolio owned by the University of Southampton, which is exclusively licensed to Synairgen. Using in vitro human models, it was discovered

FluMist is indicated for the prevention of influenza and for the active immunization of patients from 2 years to 49 years of age against influenza disease linked with

The NDA filling is backed by complete clinical and manufacturing program of MoxDuo IR. The NDA filing will help QRxPharma to register the drug in Europe, Australia, Canada

Developed by GW Pharma, Sativex oromucosal spray is indicated as a treatment for the relief of spasticity in multiple sclerosis (MS). The spray is already been marketed in

Nizatidine is indicated for the treatment for gastric and duodenal ulcers. It blocks one of the chemicals (histamine) that stimulates the production of stomach acid. Following the approval,

The vaccine showed almost 90% difference in viral count in HIV-infected patients in comparison to placebo group, following a single vaccine injection. SEEK claims its HIV-v vaccine targets

The results of the trial demonstrated that levomilnacipran showed improvement in all dose groups, in comparison to placebo. Levomilnacipran, a sustained-release formulation, once-daily treatment was well tolerated in

The tie up aims for the development of practical synthetic routes to complex natural products of importance for the treatment of skin diseases. LEO Pharma New Product Discovery